Yang, Lin

Breast cancer is the most common malignancy among women worldwide, posing a serious threat to women’s physical and mental health. To address this significant global public health challenge, the Guidelines for the Integrated Diagnosis and Treatment of Breast Cancer with Traditional Chinese and Western Medicine working group, adhering to the principles of evidence-based medicine, has proposed a comprehensive and holistic diagnostic and therapeutic pathway. This pathway integrates the core concepts of traditional Chinese medicine (TCM), such as holistic views and syndrome differentiation and treatment, with the latest advances in breast cancer treatment from both domestic and international perspectives. It objectively evaluates the role of integrated Chinese and western medicine in the all-encompassing and full-cycle management of breast cancer across different phases: the acute phase (perioperative, chemotherapy, and radiotherapy periods), early consolidation phase, late palliative care phase, and follow-up period addressing accompanying symptoms (eg, cancer-related fatigue, bone and joint symptoms). Highlighting the unique features of TCM, the guidelines provide a model for integrated breast cancer treatment for clinicians at various levels of health care institutions. This article offers a detailed interpretation of the guideline’s key highlights and 11 PICO questions concerning TCM management throughout the breast cancer continuum, aiming to enhance the understanding, application, and promotion of the guidelines.

Abstract Heregulin internalization to the nucleus is mediated via binding to Nucleolin Lin Yang, and Ruth Lupu. Department of Laboratory Medicine and Pathology, Mayo Clinic Foundation, Rochester, Minnesota 55902 Heregulin (HRG) is known as a soluble secreted growth factor of EGF-like family, which binds and activates HER3 and HER4 and transactivates HER2 and HER1 receptors. It has been shown that HRG translocates to the nucleus in triple negative breast cancer cells that express high level of HRG. The mechanism by which HRG translocates to the nucleus is still unknown. We have recently uncovered that Nucleolin binds to Heregulin and allows HRG to translocate to the nucleus. Mass spectrometry analysis revealed that multifunctional protein Nucleolin is a major HRG-associated protein. Using co-immunoprecipitation we confirmed HRG interacts with Nucleolin in both endogenous and ectopic levels. Then, we made deleted mutants of HRG to map the Nucleolin binding domain on HRG and we found that Nucleolin binds to HRG on its N-terminus which contains a putative nuclear localization signal (NLS). Remarkably, in these cells we found a striking peri-nuclear accumulation when Nucleolin was knocked down. These results show for the first time that HRG translocate to the nucleus mediated by Nucleolin binding in breast cancer cells. Importantly, the nuclear function of HRG remains as a positive regulator of chemosensitization. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 271.